AR-Based Motor Rehabilitation for Children With CP (PSYCHO-AR-REH)

June 25, 2026 updated by: Rudolf Psotta, College of Physical Education and Sport PALESTRA

Digitalization of Rehabilitation Care for Children With Motor Disorders Using Augmented Reality Technologies

The aim of the project is to create a digital system for cognitive-oriented rehabilitation of the central neuromuscular diseases (CND) with the use of augmented reality (AR) technology in children. Solving the project supports the professional-oriented digital literacy of professionals in rehabilitation institutions in the Czech Republic (CR). With the applied research, the software will be developed for the training of fine and gross motor skills, postural control and walking in the AR environment for children with cerebral palsy and verified in the practice of professionals in rehabilitation. The project aims to modernization and increase of the effectiveness of the work of professionals in rehabilitation institutions in the CR. The project is based on an interdisciplinary approach.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Medical diagnosis of spastic hemiparesis or diparesis types cerebral palsy
  • The level of motor skills was at levels I and II according to the Gross Motor Function Classification System (GMFCS)
  • spasticity of grade 2 or less diagnosed with the Modified Ashworth Scale (MAS)
  • Ability to walk at least 10 meters without aids and without the support of a therapist

Exclusion Criteria:

  • no neurological disease other than CP
  • no visual impairment with exception of short-sightedness
  • Children is not able to follow instructions during testing and training
  • Injection treatment of anti-spastic medication in the last 3 months
  • Lower limb surgery within the past 12 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental group
Behavioral: Conventional physical therapy
Traditional spa treatment comprising hydrotherapy and physical therapy.
Behavioral: AR-based therapy
The child wore Meta Quest 3 (Meta Platforms, Menlo Park, California, USA) VR/AR goggles during the exercises. Our custom exercise applications were running on the device. They provide brief verbal instructions at the start of each exercise. During the exercise, they also give short cognitive prompts to support focused attention.
Active Comparator: Control group
conventional physical therapy program
Behavioral: Conventional physical therapy
Traditional spa treatment comprising hydrotherapy and physical therapy.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Speed of 10-meter walk test (m/s)
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Speed (m/s): average speed of the walk 10 metres (10MWT)
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Cadence (steps/min)
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Number of half-steps in one minute. Data will be analyzed with the G-Studio software (BTS G-Walk, BTS Bioengineering)
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Support phase (% cycle)
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The average value of the durations of the right and left support phases as percentages of the duration of the gait cycle. Data will be analyzed with the G-Studio software (BTS G-Walk, BTS Bioengineering).
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Swing Phase (% Cycle)
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The average value of the durations of the right and left swing phases as percentages of the duration of the gait cycle. Data will be analyzed with the G-Studio software (BTS G-Walk, BTS Bioengineering).
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Symmetry index of pelvic tilt
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The movements of the pelvis in the three principal planes are evaluated using symmetry indexes between the right and left gait cycle. Non-pathological subjects show an index greater than 90. The pelvic tilt, is the sagittal component of 3D pelvic movement. Data will be analyzed with the G-Studio software (BTS G-Walk, BTS Bioengineering).
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Symmetry index of pelvic obliquity
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The movements of the pelvis in the three principal planes are evaluated using symmetry indexes between the right and left gait cycle. Non-pathological subjects show an index greater than 90. The pelvic tilt, is the frontal component of 3D pelvic movement. Data will be analyzed with the G-Studio software (BTS G-Walk, BTS Bioengineering).
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
Symmetry index of pelvic rotation
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The movements of the pelvis in the three principal planes are evaluated using symmetry indexes between the right and left gait cycle. Non-pathological subjects show an index greater than 90. The pelvic tilt, is the transverse component of 3D pelvic movement. Data will be analyzed with the G-Studio software (BTS G-Walk, BTS Bioengineering).
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The Pediatric balance scale (PBS)
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
The Pediatric Balance Scale is a modified version of the Berg Balance Scale. The scale consists of 14 balance-related test items that are scored from 0 points (lowest function) to 4 points (highest function) with a maximum score of 56 points. Higher total scores suggest that the child has good balance ability.
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
One-Leg Balance (valuated by the time the child is able to maintain the position)
Time Frame: Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)
In this task, the child is asked to stand on one leg on a balance board or other unstable surface. Each leg is tested separately. The child must maintain balance for a maximum of 30 seconds. The task is assessed in accordance with the MABC-2 manual.
Change from pre-intervention (first day) to post-intervention (last day of 4-week motor training program)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
College of Physical Education and Sport PALESTRA

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Charles University, Czech Republic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 11, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 17, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 24, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 30, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TQ01000031

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings